Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05219656
Other study ID # R19617
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2009
Est. completion date January 1, 2022

Study information

Verified date January 2022
Source Tampere University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The efficacy and safety of Cyclosporine A as rescue therapy for acute severe ulcerative colitis in long-term follow-up.


Description:

All UC patients treated with CyA in Tampere University Hospital between 2009 and 2018 were reviewed from patient records and analyzed. Amelioration of UC was defined as clinical response for rescue therapy with no need for colectomy or third-line rescue therapy at the same hospitalization as index flare. Relapse was defined as requiring further Cs treatment, re-hospitalization, biologicals, small molecules, or colectomy later in follow-up. Patients were followed-up from the date of index flare until colectomy, death, or the end of observation period. Adverse events related to treatment were assessed throughout the duration of treatment. Surgical complications were defined by using Clavien-Dindo classification (grade III-V classified as severe complications). The surgical complications in Cyclosporine-treated patients were compared to all patients operated for treatment refractor UC in Tampere University Hospital within the same follow-up period.


Recruitment information / eligibility

Status Completed
Enrollment 182
Est. completion date January 1, 2022
Est. primary completion date December 30, 2018
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Patients admitted to hospital for acute flare of UC and treated with CyA rescue therapy. - Age 16 or over Exclusion Criteria: -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cyclosporine A
Rescue therapy in acute severe ulcerative colitis

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tampere University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Response Clinical response for CyA with no need for colectomy or further enhancement of treatment with infliximab at the same hospitalization ad index flare From january 2009 to december 2018
Primary Remission Remission was defined as no need for further corticosteroids, re-hospitalization, enhancement of treatment with biologicals or small molecules or colectomy within follow-up. From january 2009 to december 2018
Primary Adverse events Reported treatment related adverse events. From january 2009 to december 2018
Primary Surgical complications Reported surgical complications. From January 2009 to December 2018
See also
  Status Clinical Trial Phase
Recruiting NCT05867329 - A Trial for Acute Severe Ulcerative Colitis Phase 4
Recruiting NCT05466890 - Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC) Phase 2
Active, not recruiting NCT04925973 - Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management Phase 2
Completed NCT03578692 - Indicators Predicting Surgery in Acute Severe Ulcerative Colitis(ASUC)
Recruiting NCT05998213 - Transfer of Feces in Ulcerative Colitis 2 Phase 2